Toggle menu

MAPP2

Start date:
June 2018
End date:
June 2020
Co-ordinated by:
Rachel O'Brien
Main trial site:
Royal Infimary Edinburgh

The development of a new point of care test will detect miR-122 and allow point of care diagnosis of paracetamol toxicity with the aim of improved patient stratification on presentation to hospital and, therefore, improve patient care.

The aim of the study is to establish a biobank of human serum samples from patients with paracetamol overdose to develop and test the performance of our point of care test. This is a prospective, observational cohort study of participants aged 16 years or over presenting to the ED/AMU aiming to recruit 326 participants.

Chief Investigator

Dr James Dear

Consultant in Acute Medicine & Toxicology

Research Team

Rachel O'Brien

Lead Research Nurse

Caroline Blackstock

AMU Senior Research Nurse

More EMERGE Trials

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

Read more

ATTEST2

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

Auditting, monitoring and optimising the transfusion support given to trauma patients in Scotland

Read more

Code Red

Transfusion and Laboratory support in Trauma Group Code Red Audit

Evaluating the role of early CT Coronary Angiography on patients with suspected or confirmed Acute Coronary Syndrome.

Read more

RAPID-CTCA

Evaluating the role of early CT Coronary Angiography